glp 1 covered by medicare obesity drug GLP-1 coverage starting July GLP-1 Weight-Loss Drug Demonstration Begins

In rabbit models, intra-articular injection of scAAV2 encoding interleukin-1 receptor antagonist (IL-1Ra) yielded sustained therapeutic protein expression in both inflamed and normal joints for at least two weeks, with minimal immune activation or joint pathology (178)

Always look for third-party testing and a lack of synthetic fillers to ensure you are supporting your health without unintended risks

Some patients use MOTS-C continuously for chronic metabolic conditions

The biomarker changes (lower blood pressure, better lipid profile) are favourable and create a reasonable prior expectation, but the dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is not expected to report until late 2027 or early 2028